160 related articles for article (PubMed ID: 38413708)
1. Isocitrate dehydrogenase 2 regulates the proliferation of triple-negative breast cancer through the ferroptosis pathway.
Zhang C; Zhou Y; Chen T; Bhushan S; Sun S; Zhang P; Yang Y
Sci Rep; 2024 Feb; 14(1):4732. PubMed ID: 38413708
[TBL] [Abstract][Full Text] [Related]
2. PGM5P3-AS1 regulates MAP1LC3C to promote cell ferroptosis and thus inhibiting the malignant progression of triple-negative breast cancer.
Qi L; Sun B; Yang B; Lu S
Breast Cancer Res Treat; 2022 Jun; 193(2):305-318. PubMed ID: 35325342
[TBL] [Abstract][Full Text] [Related]
3. POU2F2-mediated upregulation of lncRNA
Li J; Li PT; Wu W; Ding BN; Wen YG; Cai HL; Liu SX; Hong T; Zhang JF; Zhou JD; Qian LY; Du J
Epigenomics; 2024 Feb; 16(4):215-231. PubMed ID: 38318853
[TBL] [Abstract][Full Text] [Related]
4. Shuganning injection, a traditional Chinese patent medicine, induces ferroptosis and suppresses tumor growth in triple-negative breast cancer cells.
Du J; Wang L; Huang X; Zhang N; Long Z; Yang Y; Zhong F; Zheng B; Lan W; Lin W; Ma W
Phytomedicine; 2021 May; 85():153551. PubMed ID: 33827043
[TBL] [Abstract][Full Text] [Related]
5. Serine Biosynthesis Is a Metabolic Vulnerability in IDH2-Driven Breast Cancer Progression.
Barnabas GD; Lee JS; Shami T; Harel M; Beck L; Selitrennik M; Jerby-Arnon L; Erez N; Ruppin E; Geiger T
Cancer Res; 2021 Mar; 81(6):1443-1456. PubMed ID: 33500247
[TBL] [Abstract][Full Text] [Related]
6. Ferroptosis-enhanced chemotherapy for triple-negative breast cancer with magnetic composite nanoparticles.
Zhang J; Zhou K; Lin J; Yao X; Ju D; Zeng X; Pang Z; Yang W
Biomaterials; 2023 Dec; 303():122395. PubMed ID: 37988899
[TBL] [Abstract][Full Text] [Related]
7. PGRMC1 promotes triple-negative breast cancer cell growth via suppressing ferroptosis.
Zhao Y; Ruan X; Cheng J; Xu X; Gu M; Mueck AO
Climacteric; 2023 Apr; 26(2):135-142. PubMed ID: 36724820
[TBL] [Abstract][Full Text] [Related]
8. An iron metabolism and immune related gene signature for the prediction of clinical outcome and molecular characteristics of triple-negative breast cancer.
Li XF; Fu WF; Zhang J; Song CG
BMC Cancer; 2022 Jun; 22(1):619. PubMed ID: 35668369
[TBL] [Abstract][Full Text] [Related]
9. WTAP Mediates NUPR1 Regulation of LCN2 Through m
Tan M; He Y; Yi J; Chen J; Guo Q; Liao N; Peng L
Biochem Genet; 2024 Apr; 62(2):876-891. PubMed ID: 37477758
[TBL] [Abstract][Full Text] [Related]
10. SRSF1 inhibits ferroptosis and reduces cisplatin chemosensitivity of triple-negative breast cancer cells through the circSEPT9/GCH1 axis.
Song X; Wang X; Chen X; Yu Z; Zhou Y
J Proteomics; 2024 Feb; 292():105055. PubMed ID: 38040194
[TBL] [Abstract][Full Text] [Related]
11. Tiliroside induces ferroptosis to repress the development of triple-negative breast cancer cells.
Hu C; Zhao JF; Wang YM; Wu XL; Ye L
Tissue Cell; 2023 Aug; 83():102116. PubMed ID: 37301139
[TBL] [Abstract][Full Text] [Related]
12. Neutrophil extracellular traps mediate TLR9/Merlin axis to resist ferroptosis and promote triple negative breast cancer progression.
Yao L; Sheng X; Dong X; Zhou W; Li Y; Ma X; Song Y; Dai H; Du Y
Apoptosis; 2023 Oct; 28(9-10):1484-1495. PubMed ID: 37368176
[TBL] [Abstract][Full Text] [Related]
13. Regulatory network of ferroptosis and autophagy by targeting oxidative stress defense using sulfasalazine in triple-negative breast cancer.
Takatani-Nakase T; Ikushima C; Sakitani M; Nakase I
Life Sci; 2024 Feb; 339():122411. PubMed ID: 38184272
[TBL] [Abstract][Full Text] [Related]
14. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy.
Yang F; Xiao Y; Ding JH; Jin X; Ma D; Li DQ; Shi JX; Huang W; Wang YP; Jiang YZ; Shao ZM
Cell Metab; 2023 Jan; 35(1):84-100.e8. PubMed ID: 36257316
[TBL] [Abstract][Full Text] [Related]
15. A Novel Derivative of Curcumol, HCL-23, Inhibits the Malignant Phenotype of Triple-Negative Breast Cancer and Induces Apoptosis and HO-1-Dependent Ferroptosis.
Zhao P; Song H; Gao F; Chen L; Qiu J; Jin J; Pan C; Tang Y; Chen M; Pan Y; Li Y; Huang L; Yang J; Hao X
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110625
[TBL] [Abstract][Full Text] [Related]
16. Wild-type IDH2 is a therapeutic target for triple-negative breast cancer.
Li JJ; Yu T; Zeng P; Tian J; Liu P; Qiao S; Wen S; Hu Y; Liu Q; Lu W; Zhang H; Huang P
Nat Commun; 2024 Apr; 15(1):3445. PubMed ID: 38658533
[TBL] [Abstract][Full Text] [Related]
17. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
[TBL] [Abstract][Full Text] [Related]
18. Ferroptosis: the emerging player in remodeling triple-negative breast cancer.
Li J; He D; Li S; Xiao J; Zhu Z
Front Immunol; 2023; 14():1284057. PubMed ID: 37928550
[TBL] [Abstract][Full Text] [Related]
19. Gankyrin inhibits ferroptosis through the p53/SLC7A11/GPX4 axis in triple-negative breast cancer cells.
Lei M; Zhang YL; Huang FY; Chen HY; Chen MH; Wu RH; Dai SZ; He GS; Tan GH; Zheng WP
Sci Rep; 2023 Dec; 13(1):21916. PubMed ID: 38081931
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of cannabinoid receptor type 1 sensitizes triple-negative breast cancer cells to ferroptosis via regulating fatty acid metabolism.
Li P; Lin Q; Sun S; Yang N; Xia Y; Cao S; Zhang W; Li Q; Guo H; Zhu M; Wang Y; Zheng Z; Li S
Cell Death Dis; 2022 Sep; 13(9):808. PubMed ID: 36130940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
